ENDONOVO THERAPEUTICS, INC. Operating Income Loss

Quick Answer

ENDONOVO THERAPEUTICS, INC. reported Operating Income Loss of -$3.26 million for the year ending 2022.

  • ENDONOVO THERAPEUTICS, INC. showed a decrease of -46.6% in Operating Income Loss from 2021 to 2022.
  • This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
  • XBRL data for this metric is available from 2010 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 11 years of available data (2010 to 2022), ENDONOVO THERAPEUTICS, INC.'s Operating Income Loss has declined by 4,085.8%.
  • Historical annual values: Fiscal year 2022: -$3.26 million | Fiscal year 2021: -$2.23 million | Fiscal year 2020: -$2.91 million | Fiscal year 2019: -$3.81 million | Fiscal year 2018: -$4.16 million | Fiscal year 2017: -$4.60 million | Fiscal year 2016: -$5.41 million | Fiscal year 2015: -$2.56 million | Fiscal year 2014: -$2.19 million | Fiscal year 2011: -$95.5 thousand | Fiscal year 2010: -$78.0 thousand.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: